Department of Radiation Oncology, University Medical Center Bonn (UKB), Bonn, Germany.
Department of Oral, Maxillofacial and Plastic Surgery, University Medical Center Bonn (UKB), Bonn, Germany.
Head Neck. 2022 Aug;44(8):1885-1895. doi: 10.1002/hed.27103. Epub 2022 May 30.
Decision regret reflects patient satisfaction with treatment choice and is associated with quality of life. This study aimed to identify patient, tumor, and treatment characteristics and post-treatment symptoms associated with decision regret among patients with head and neck cancer who underwent surgery and adjuvant radiotherapy.
In this cross-sectional study, patients completed a questionnaire during a telephone interview. The questionnaire included the Decision Regret Scale (DRS) and several specific symptom-related items. By the time of data collection, all patients had concluded their radiotherapy a minimum of 2 months and maximum of 3.3 years prior.
Among the 108 patients included, 40.5% reported no regret, 30.1% reported mild regret, and 29.4% reported moderate to strong regret. A higher DRS score was most strongly associated with a lower single fraction dose and more restriction in everyday life. Higher DRS scores were also correlated with trouble speaking, trouble swallowing, pain in irradiated areas, dissatisfaction with one's appearance, feeling sad, and worry over one's future health.
Based on these findings, we recommended that patients with head and neck cancer undergoing adjuvant radiation receive psychosocial support and adequate treatment of late toxicity-related symptoms. When confronted with different therapeutic options, radiotherapy with a higher single fraction dose (i.e., hypofractionation) may be preferred due to its association with lower decision regret.
决策后悔反映了患者对治疗选择的满意度,并与生活质量相关。本研究旨在确定与头颈部癌症患者接受手术和辅助放疗后决策后悔相关的患者、肿瘤和治疗特征以及治疗后症状。
在这项横断面研究中,患者通过电话访谈完成了一份问卷。问卷包括决策后悔量表(DRS)和几个特定的与症状相关的项目。在数据收集时,所有患者均已完成放疗至少 2 个月,最长 3.3 年。
在纳入的 108 例患者中,40.5%的患者报告没有后悔,30.1%的患者报告有轻度后悔,29.4%的患者报告有中度至强烈的后悔。较高的 DRS 评分与较低的单次剂量和日常生活受限最密切相关。较高的 DRS 评分还与言语困难、吞咽困难、照射区域疼痛、对自己外貌不满意、感到悲伤以及对未来健康的担忧相关。
基于这些发现,我们建议接受辅助放疗的头颈部癌症患者接受社会心理支持和对晚期毒性相关症状的充分治疗。当面临不同的治疗选择时,由于与较低的决策后悔相关,较高单次剂量(即低分割)的放疗可能更受青睐。